Literature DB >> 22247121

Chronic diseases, chromosomal abnormalities, and congenital malformations as risk factors for respiratory syncytial virus hospitalization: a population-based cohort study.

Kim Kristensen1, Thomas Hjuler, Henrik Ravn, Eric A F Simões, Lone G Stensballe.   

Abstract

BACKGROUND: Little is known about how chronic conditions other than prematurity, heart disease, and Down syndrome affect the risk and severity of hospitalization for respiratory syncytial virus (RSV). We assess the risk and severity of RSV hospitalization in children with chronic conditions in this register-based, population-based cohort study.
METHODS: Data on RSV tests, maternal smoking, siblings, single parenthood, mode of delivery, gestational age at birth, major surgery, asthma diagnosis, chronic conditions, and hospitalization and discharge dates were obtained from the Danish RSV database, the National Patient and Birth Registries, and the Civil Registration System. STATISTICS: Cox regression models were used to estimate incidence rate ratios (IRRs) for RSV hospitalization between groups stratified by sex and date of birth. Duration of RSV hospitalization was analyzed in a linear regression and reported as geometric mean ratios.
RESULTS: A total of 391 983 children aged 0-23 months were included in the analysis. A total of 10,616 (2.7%) had a diagnosis for chronic disease. IRRs (95% confidence intervals) for RSV hospitalization in children with any congenital or acquired chronic condition were 2.18 (2.01-2.36) and 2.25 (1.94-2.61), respectively. Several new risk factors for RSV hospitalization, including malformations, interstitial lung disease, neuromuscular disease, liver disease, chromosomal abnormalities, congenital immunodeficiencies, and inborn errors of metabolism, were identified. Duration of RSV hospitalization was increased in many chronic conditions.
CONCLUSIONS: Chronic disease per se is an important risk factor for RSV hospitalization.

Entities:  

Mesh:

Year:  2012        PMID: 22247121     DOI: 10.1093/cid/cir928

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  40 in total

1.  Palivizumab use in infants with Down syndrome-report from the German Synagis™ Registry 2009-2016.

Authors:  Arne Simon; Susanne Gehrmann; Gudrun Wagenpfeil; Stefan Wagenpfeil
Journal:  Eur J Pediatr       Date:  2018-04-12       Impact factor: 3.183

2.  Novel inflammatory markers, clinical risk factors and virus type associated with severe respiratory syncytial virus infection.

Authors:  Christy M Tabarani; Cynthia A Bonville; Manika Suryadevara; Patrick Branigan; Dongliang Wang; Danning Huang; Helene F Rosenberg; Joseph B Domachowske
Journal:  Pediatr Infect Dis J       Date:  2013-12       Impact factor: 2.129

Review 3.  An official American Thoracic Society clinical practice guideline: classification, evaluation, and management of childhood interstitial lung disease in infancy.

Authors:  Geoffrey Kurland; Robin R Deterding; James S Hagood; Lisa R Young; Alan S Brody; Robert G Castile; Sharon Dell; Leland L Fan; Aaron Hamvas; Bettina C Hilman; Claire Langston; Lawrence M Nogee; Gregory J Redding
Journal:  Am J Respir Crit Care Med       Date:  2013-08-01       Impact factor: 21.405

4.  Respiratory syncytial virus prophylaxis in infants with congenital airway anomalies compared to standard indications and complex medical disorders.

Authors:  Bosco Paes; Doyoung Kim; Mahwesh Saleem; Sophie Wong; Ian Mitchell; Krista L Lanctot
Journal:  Eur J Pediatr       Date:  2019-01-04       Impact factor: 3.183

5.  Respiratory syncytial virus prophylaxis in cystic fibrosis: the Canadian registry of palivizumab data (2005-2016).

Authors:  Ian Mitchell; S K Wong; B Paes; M Ruff; C Bjornson; A Li; K L Lanctôt
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-05-04       Impact factor: 3.267

6.  Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need?

Authors:  Candice Bjornson; Parco Chan; Abby Li; Bosco Paes; Krista L Lanctôt; Ian Mitchell
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-03-19       Impact factor: 3.267

7.  Nasopharyngeal Microbiota, Host Transcriptome, and Disease Severity in Children with Respiratory Syncytial Virus Infection.

Authors:  Wouter A A de Steenhuijsen Piters; Santtu Heinonen; Raiza Hasrat; Eleonora Bunsow; Bennett Smith; Maria-Carmen Suarez-Arrabal; Damien Chaussabel; Daniel M Cohen; Elisabeth A M Sanders; Octavio Ramilo; Debby Bogaert; Asuncion Mejias
Journal:  Am J Respir Crit Care Med       Date:  2016-11-01       Impact factor: 21.405

8.  Respiratory syncytial virus (RSV) infection in children with medical complexity.

Authors:  A Lim; M L Butt; J Dix; L Elliott; B Paes
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-10-29       Impact factor: 3.267

Review 9.  Respiratory syncytial virus--a comprehensive review.

Authors:  Andrea T Borchers; Christopher Chang; M Eric Gershwin; Laurel J Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2013-12       Impact factor: 8.667

10.  Respiratory syncytial virus-associated hospitalizations over three consecutive seasons in children with congenital heart disease.

Authors:  B Resch; S Kurath-Koller; J Hahn; W Raith; M Köstenberger; A Gamillscheg
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-04-28       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.